

1 A bill to be entitled
 2 An act relating to controlled substances; amending s.
 3 893.02, F.S.; amending the definition of "cannabis";
 4 amending s. 893.03, F.S.; scheduling a certain drug
 5 product containing cannabidiol to Schedule V;
 6 providing an effective date.

7
 8 Be It Enacted by the Legislature of the State of Florida:

9
 10 Section 1. Subsection (3) of section 893.02, Florida
 11 Statutes, is amended to read:

12 893.02 Definitions.—The following words and phrases as
 13 used in this chapter shall have the following meanings, unless
 14 the context otherwise requires:

15 (3) "Cannabis" means all parts of any plant of the genus
 16 Cannabis, whether growing or not; the seeds thereof; the resin
 17 extracted from any part of the plant; and every compound,
 18 manufacture, salt, derivative, mixture, or preparation of the
 19 plant or its seeds or resin. The term does not include
 20 "marijuana," as defined in s. 381.986, if manufactured,
 21 possessed, sold, purchased, delivered, distributed, or
 22 dispensed, in conformance with s. 381.986. The term does not
 23 include a drug product described in s. 893.03(5)(d).

24 Section 2. Paragraph (d) is added to subsection (5) of
 25 section 893.03, Florida Statutes, to read:

HB 7107

2019

26 893.03 Standards and schedules.—The substances enumerated
27 in this section are controlled by this chapter. The controlled
28 substances listed or to be listed in Schedules I, II, III, IV,
29 and V are included by whatever official, common, usual,
30 chemical, trade name, or class designated. The provisions of
31 this section shall not be construed to include within any of the
32 schedules contained in this section any excluded drugs listed
33 within the purview of 21 C.F.R. s. 1308.22, styled "Excluded
34 Substances"; 21 C.F.R. s. 1308.24, styled "Exempt Chemical
35 Preparations"; 21 C.F.R. s. 1308.32, styled "Exempted
36 Prescription Products"; or 21 C.F.R. s. 1308.34, styled "Exempt
37 Anabolic Steroid Products."

38 (5) SCHEDULE V.—A substance, compound, mixture, or
39 preparation of a substance in Schedule V has a low potential for
40 abuse relative to the substances in Schedule IV and has a
41 currently accepted medical use in treatment in the United
42 States, and abuse of such compound, mixture, or preparation may
43 lead to limited physical or psychological dependence relative to
44 the substances in Schedule IV.

45 (d) A drug product in finished dosage formulation that has
46 been approved by the United States Food and Drug Administration
47 that contains cannabidiol (2-[1R-3-methyl-6R-(1-methylethenyl)-
48 2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) derived from
49 cannabis and no more than 0.1 percent (w/w) residual
50 tetrahydrocannabinols.

HB 7107

2019

51 | Section 3. This act shall take effect upon becoming a law. |